Frontiers in OncologyCancer BiologyPeer-reviewed journal article
Auranofin and reactive oxygen species inhibit protein synthesis and regulate the level of the PLK1 protein in Ewing sarcoma cells.
Joseph A. Haight, Stacia L. KoppenhaferiD, Elizabeth L. GearyiD, David J. GordoniD
Abstract
Novel therapeutic approaches are needed for the treatment of Ewing sarcoma tumors. We previously identified that Ewing sarcoma cell lines are sensitive to drugs that inhibit protein translation. However, translational and therapeutic approaches to inhibit protein synthesis in tumors are limited. In this work, we identified that reactive oxygen species, which are generated by a wide range of chemotherapy and other drugs, inhibit protein synthesis and reduce the level of critical proteins that support tumorigenesis in Ewing sarcoma cells. In particular, we identified that both hydrogen peroxide and auranofin, an inhibitor of thioredoxin reductase and regulator of oxidative stress and reactive oxygen species, activate the repressor of protein translation 4E-BP1 and reduce the levels of the oncogenic proteins RRM2 and PLK1 in Ewing and other sarcoma cell lines. These results provide novel insight into the mechanism of how ROS-inducing drugs target cancer cells via inhibition of protein translation and identify a mechanistic link between ROS and the DNA replication (RRM2) and cell cycle regulatory (PLK1) pathways.
- organism: human
- assay: proteomics
- research focus: cancer & tumor microenvironment
- approach: experimental assay
- Citations
- 5
- FWCI
- 0.88
- Field percentile
- top 25%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Oncogenic hijacking of a developmental transcription factor evokes therapeutic vulnerability for ROS-induction in Ewing sarcoma
A. Marchetto, S. Ohmura, … T. G. P. Grunewald·bioRxiv·Mar 14, 2019
- A novel combination of CDK4/6 and PI3K inhibitors exhibits highly synergistic activity and translational potential in Ewing sarcoma.
Helen F. Gloege, Maria Ana Isabel C. De Los Santos, … Brian D. Crompton·Translational OncologyPeer-reviewed·Jun 18, 2026
- Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma
S. Ohmura, A. Marchetto, … T. G. P. Grunewald·bioRxiv·Mar 4, 2021
- EXO1 Facilitates MiDAS and Prevents Genome Instability and Cell Death in Ewing Sarcoma
Joaquín Olmedo-Pelayo, Laura Lobo-Selma, … Enrique de Álava·bioRxiv·Jun 9, 2026
- Glutaredoxin 3 (GLRX3) confers a fusion oncogene-dependent vulnerability to Ewing sarcoma
Endrit Vinca, Anna C. Ehlers, … Shunya Ohmura·bioRxiv·Apr 24, 2024
- Dysregulated heparan sulfate proteoglycan metabolism promotes Ewing sarcoma tumor growth
E. Vasileva, M. Warren, … J. F. Amatruda·bioRxiv·May 25, 2021